Histone deacetylase 4 is regulated by microRNA 128 in SH-SY5Y cells of Parkinson’s disease
Objective: To explore the mechanisms and regulating effects of microRNA 128 in Parkinson's disease (PD). Background: PD is the second common progressive neurodegenerative disorder characterized…Disruption of circadian rhythm function and anti-oxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson’s disease model
Objective: Our aim is to investigate whether the altered expression of clock genes is associated with the dysfunction of the anti-oxidative ability in Parkinson's disease.…Evaluation of the role of oxidative stress in Parkinson’s disease and Parkinson plus syndrome
Objective: To evaluate the role of oxidative stress in peripheral blood in patients with Parkinson's disease (PD) and Parkinson plus syndrome (PPS). Background: Slight excess…Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study
Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…Long term recordings of subthalamic ocillatory activity in patients with Parkinson’s disease
Objective: The aim of this study was to investigate the stability of beta oscillations (13 - 30 Hz) in the subthalamic nucleus (STN) of patients…APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation
Objective: To investigate whether sodium butyrate (NaB) could enhance autophagy and thus exert a neuroprotective effect through the modulation of α-synuclein in animal models of…Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease
Objective: Determine the pharmacokinetic/pharmacodynamic effects of APL-130277 on OFF episodes in patients with Parkinson's disease (PD). Background: APL-130277 is a sublingual film being studied in…Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…Effect of vibration on motor performance: A new intervention to improve bradykinesia in Parkinson’s disease?
Objective: Here we propose to test whether bradykinesia in Parkinson's disease (PD) can be ameliorated by non-invasive interventions (peripheral tactile vibration) that decrease sensory precision.…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.